Clinical trials: LAM
Hepatitis B, Chronic
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV).
- Trial name
- NCT01095835
- Testing
- Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
- Where
- 22 sites in Italy
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
This is a prospective, non-interventional, multi-center study, in participants with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection.
- Trial name
- URBAN (NCT03754803)
- Testing
- HIV symptom distress module (SDM) questionnaire, HIV treatment satisfaction questionnaire (TSQ)
- Where
- 18 sites in Germany
- Volunteers
- 376 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine…
- Trial name
- NCT02603120
- Testing
- ABC/DTG/3TC, B/F/TAF
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
HIV Infections, AIDS-Associated Nephropathy
A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease
The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney…
- Trial name
- NCT00002397
- Testing
- Nelfinavir mesylate, Saquinavir, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and…
- Trial name
- NCT00612898
- Testing
- apricitabine, lamivudine
- Where
- 100 sites in United States, Australia and 9 more
- Volunteers
- 239 people
- Sponsor
- Avexa
AIDS
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
- Trial name
- NCT00207168
- Testing
- Compliance
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B.
- Trial name
- NCT02598063
- Testing
- Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a
- Where
- 12 sites in China, Hong Kong
- Volunteers
- 255 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.
- Trial name
- NCT00042393
- Testing
- Adefovir Dipivoxil
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI]) with and without hydroxyurea (HU).
- Trial name
- NCT00005018
- Testing
- Hydroxyurea, Abacavir sulfate, Efavirenz
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Glaxo Wellcome
Hepatitis B, Chronic
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine
- Trial name
- DEFINE (NCT00410202)
- Testing
- Entecavir, Tenofovir, Adefovir
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 629 people
- Sponsor
- Bristol-Myers Squibb
Infection, Human Immunodeficiency Virus
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study.
- Trial name
- NCT02105987
- Testing
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Where
- 103 sites in United States, Canada and 1 more
- Volunteers
- 555 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients.
- Trial name
- NCT00002401
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.
- Trial name
- NCT00002436
- Testing
- Lamivudine, Zidovudine, Zalcitabine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
Hepatitis B, Chronic
Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)
The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.
- Trial name
- NCT01376154
- Testing
- Lamivudine
- Volunteers
- 342 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA levels by PCR (log10 copies/mL) at Week 22
- Trial name
- NCT01022801
- Testing
- Entecavir
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Infection, Human Immunodeficiency Virus
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
- Trial name
- ING112276 (NCT00951015)
- Testing
- GSK1349572, efavirenz
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 208 people
- Sponsor
- ViiV Healthcare
Healthy Subjects, Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01366547
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
- Trial name
- NCT00051038
- Testing
- Entecavir
- Where
- 5 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
- Trial name
- NCT00005106
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaxo Wellcome